Hikal
- Advice
- Hold
Hikal Performance
Day Range
- Low 298.05
- High 304.9
52 Week Range
- Low 260.75
- High 427.8
- Open Price304.9
- Previous Close302.3
- Volume59948
Start SIP in Hikal
Start SIPHikal Investment Rating
-
Master Rating:
-
Hikal has an operating revenue of Rs. 2,032.29 Cr. on a trailing 12-month basis. An annual revenue growth of 4% is not great, Pre-tax margin of 5% is okay, ROE of 6% is fair but needs improvement. The company has a reasonable debt to equity of 43%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 83 which is a GOOD score indicating consistency in earnings, a RS Rating of 16 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 99 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
---|---|---|---|---|---|---|
Oper Rev Qtr Cr | 388 | 538 | 538 | 557 | 371 | 501 |
Operating Expenses Qtr Cr | 338 | 457 | 466 | 489 | 356 | 441 |
Operating Profit Qtr Cr | 50 | 88 | 75 | 70 | 23 | 61 |
Depreciation Qtr Cr | 28 | 27 | 28 | 27 | 27 | 24 |
Interest Qtr Cr | 14 | 13 | 13 | 11 | 11 | 8 |
Tax Qtr Cr | 3 | 13 | 9 | 8 | -3 | 8 |
Net Profit Qtr Cr | 7 | 36 | 26 | 25 | -9 | 21 |
Hikal Technicals
EMA & SMA

- Bullish Moving Average
- ___
- 6
- Bearish Moving Average
- ___
- 10
- 20 Day
- ₹302.46
- 50 Day
- ₹300.15
- 100 Day
- ₹302.79
- 200 Day
- ₹312.73
- 20 Day
- ₹302.23
- 50 Day
- ₹296.4
- 100 Day
- ₹301.47
- 200 Day
- ₹318.5
Hikal Resistance and Support
Resistance | |
---|---|
First Resistance | ₹307.2 |
Second Resistance | ₹312.11 |
Third Resistance | ₹315.45 |
RSI | 50.95 |
MFI | 64.53 |
MACD Single Line | 3.08 |
MACD | 2.92 |
Support | |
---|---|
First Resistance | ₹298.95 |
Second Resistance | ₹295.61 |
Third Resistance | ₹290.7 |
Hikal Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 171,843 | 7,298,172 | 42.47 |
Week | 271,965 | 11,922,935 | 43.84 |
1 Month | 415,734 | 19,007,367 | 45.72 |
6 Month | 433,573 | 16,657,880 | 38.42 |
Hikal Result Highlights
Hikal Synopsis
NSE-Medical-Diversified
Hikal Ltd. is involved in the business activities of Manufacture of insecticides, rodenticides, fungicides, herbicides. Company’s Total Operating Revenue is Rs. 2023.03 Cr. and Equity Capital is Rs. 24.66 Cr. for the Year ended 31/03/2023. Hikal Ltd. is a Public Limited Listed company incorporated on 08/07/1988 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24200MH1988PTC048028 and registration number is 048028.Market Cap | 3,712 |
Sales | 2,032 |
Shares in Float | 3.82 |
No of funds | 69 |
Yield | 0.4 |
Book Value | 3.29 |
U/D Vol ratio | 1.1 |
LTDebt / Equity | 43 |
Alpha | -0.03 |
Beta | 1.04 |
Hikal
Owner Name | Jun-23 | Mar-23 | Dec-22 | Sep-22 |
---|---|---|---|---|
Promoters | 68.85% | 68.85% | 68.83% | 68.77% |
Mutual Funds | 2.39% | 1.79% | 1.3% | 1.1% |
Insurance Companies | 0.12% | 0.12% | 0.12% | 0.12% |
Foreign Portfolio Investors | 4.57% | 4.56% | 4.4% | 4.27% |
Individual Investors | 18.56% | 18.72% | 18.78% | 19.2% |
Others | 5.51% | 5.96% | 6.57% | 6.54% |
Hikal Management
Name | Designation |
---|---|
Mr. Jai Hiremath | Executive Chairman |
Mr. Sameer Hiremath | Managing Director |
Ms. Sugandha Hiremath | Director |
Mrs. Shivani Bhasin Sachdeva | Director |
Mr. Ranjit Shahani | Director |
Mr. Kannan Unni | Director |
Mr. Amit Kalyani | Director |
Mr. Baba Kalyani | Director |
Mr. Prakash Mehta | Director |
Mr. Shrikrishna Adivarekar | Director |
Hikal Forecast
Price Estimates
Hikal Corporate Action
Date | Purpose | Remarks |
---|---|---|
2023-08-08 | Quarterly Results | |
2023-05-29 | Audited Results & Final Dividend | |
2023-02-02 | Quarterly Results & Interim Dividend | |
2022-11-09 | Quarterly Results | |
2022-08-10 | Quarterly Results |
Date | Purpose | Remarks |
---|---|---|
2023-02-14 | INTERIM | Rs.0.60 per share(30%)Interim Dividend |
2022-09-15 | FINAL | Rs.0.40 per share(20%)Final Dividend |
2022-02-24 | INTERIM | Rs.1.20 per share(60%)Interim Dividend |
2021-08-26 | FINAL | Rs.1.00 per share(50%)Final Dividend |
2021-02-16 | INTERIM | Rs.1.00 per share(50%)Interim Dividend |
- Company Name
- CMP
- Chg(%)
- St Bk of India
- 598
- 1.7
- HDFC Life Insur.
- 653
- 1.4
- M & M
- 1605
- 1.4
- Maruti Suzuki
- 10426
- 1.4
- Tech Mahindra
- 1309
- 1.3
- Company Name
- CMP
- Chg(%)
- Cipla
- 1175
- -2.6
- Dr Reddys Labs
- 5540
- -2.3
- Wipro
- 420
- -2.1
- Power Grid Corpn
- 198
- -2.0
- Sun Pharma.Inds.
- 1129
- -1.5
Hikal FAQs
What is Share Price of Hikal ?
Hikal share price is ₹301 As on 22 September, 2023 | 10:40
What is the Market Cap of Hikal ?
The Market Cap of Hikal is ₹3717.5 Cr As on 22 September, 2023 | 10:40
What is the P/E ratio of Hikal ?
The P/E ratio of Hikal is 39.5 As on 22 September, 2023 | 10:40
What is the PB ratio of Hikal ?
The PB ratio of Hikal is 3.3 As on 22 September, 2023 | 10:40